NASDAQ:AKBA Akebia Therapeutics Q4 2023 Earnings Report $2.83 -0.09 (-3.08%) Closing price 04:00 PM EasternExtended Trading$2.85 +0.02 (+0.71%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Akebia Therapeutics EPS ResultsActual EPS-$0.04Consensus EPS -$0.04Beat/MissMet ExpectationsOne Year Ago EPS-$0.04Akebia Therapeutics Revenue ResultsActual Revenue$56.20 millionExpected Revenue$55.64 millionBeat/MissBeat by +$560.00 thousandYoY Revenue GrowthN/AAkebia Therapeutics Announcement DetailsQuarterQ4 2023Date3/14/2024TimeQ4 2023 Earnings ReleaseConference Call DateThursday, March 14, 2024Conference Call Time4:00PM ETUpcoming EarningsAkebia Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Akebia Therapeutics Earnings HeadlinesAkebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy"September 14 at 3:39 AM | americanbankingnews.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) most popular amongst individual investors who own 55% of the shares, institutions hold 43%September 6, 2025 | finance.yahoo.comThis Coin Could Explode, and it’s Hiding in Plain Sight!Crypto market dominance: 28% and growing fast Think about it: When one protocol controls nearly 30% of a trillion-dollar market, what happens to its token price when that market explodes? Our #1 Coin Report reveals exactly which protocol this is and why its dominance is just getting started.September 16 at 2:00 AM | Crypto 101 Media (Ad)Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comBrokerages Set Akebia Therapeutics, Inc. (NASDAQ:AKBA) PT at $6.75September 5, 2025 | americanbankingnews.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comSee More Akebia Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akebia Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akebia Therapeutics and other key companies, straight to your email. Email Address About Akebia TherapeuticsAkebia Therapeutics (NASDAQ:AKBA), a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders. Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach. The company has partnered with Otsuka Pharmaceutical for filing and commercialization of vadadustat in the United States, while Mitsubishi Tanabe Pharma holds rights to develop and commercialize the compound in ex-Japan territories. These alliances leverage Akebia’s scientific expertise alongside the global commercialization networks of its partners. In addition to its focus on anemia in kidney disease, Akebia evaluates novel mechanisms of action aimed at improving kidney health and patient outcomes. The company maintains clinical trial sites across North America and engages with healthcare providers, academic institutions and patient advocacy groups to support the design and execution of its studies. Under the leadership of President and Chief Executive Officer John P. Butler, Akebia continues to build its development infrastructure and prepare for potential regulatory milestones.View Akebia Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
